Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Follow-Up Questions
Talphera Inc의 CEO는 누구입니까?
Mr. Vincent Angotti은 2017부터 회사에 합류한 Talphera Inc의 Chief Executive Officer입니다.
TLPH 주식의 가격 성능은 어떻습니까?
TLPH의 현재 가격은 $0.8822이며, 전 거래일에 increased 3.78% 하였습니다.
Talphera Inc의 주요 사업 주제나 업종은 무엇입니까?
Talphera Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Talphera Inc의 시가총액은 얼마입니까?
Talphera Inc의 현재 시가총액은 $40.1M입니다
Talphera Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Talphera Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
